[1]曾宪茗.利拉鲁肽联合胰岛素强化治疗2型糖尿病的临床疗效及其对炎性反应和血管内皮功能的影响[J].医学信息,2024,37(21):39-42.[doi:10.3969/j.issn.1006-1959.2024.21.008]
　ZENG Xianming.Clinical Efficacy of Liraglutide Combined with Intensive Insulin Therapy in Type 2 Diabetes Mellitus and its Effect on Inflammatory Response and Vascular Endothelial Function[J].Journal of Medical Information,2024,37(21):39-42.[doi:10.3969/j.issn.1006-1959.2024.21.008]
点击复制

利拉鲁肽联合胰岛素强化治疗2型糖尿病的临床疗效及其对炎性反应和血管内皮功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年21期
页码:
39-42
栏目:
论著
出版日期:
2024-11-01

文章信息/Info

Title:
Clinical Efficacy of Liraglutide Combined with Intensive Insulin Therapy in Type 2 Diabetes Mellitus and its Effect on Inflammatory Response and Vascular Endothelial Function
文章编号:
1006-1959（2024）21-0039-04
作者:
曾宪茗
赣县区人民医院内分泌科，江西 赣州 341100
Author(s):
ZENG Xianming
Department of Endocrinology,Ganxian District People’s Hospital,Ganzhou 341100,Jiangxi,China
关键词:
利拉鲁肽; 胰岛素; 强化治疗; 2型糖尿病; 炎性反应; 血管内皮功能
Keywords:
Liraglutide; Insulin; Intensive treatment; Type 2 diabetes mellitus; Inflammatory reaction; Vascular endothelial function
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2024.21.008
文献标志码:
A
摘要:
目的 研究利拉鲁肽联合胰岛素强化治疗2型糖尿病的临床疗效，以及对炎性反应和血管内皮功能的影响。方法 选取2020年6月-2023年6月在我院诊治的60例2型糖尿病患者为研究对象，采用随机数字表法分为对照组和观察组，各组30例。对照组采用胰岛素强化治疗，观察组在对照组基础上给予利拉鲁肽治疗，比较两组临床疗效、血糖指标[糖化血红蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 hPG）]、炎性因子[白介素6（IL-6）、肿瘤坏死因子α（TNF-α）]水平、血管内皮功能指标[内皮素1（ET-1）、一氧化氮（NO）]，以及不良反应发生率。结果 观察组治疗总有效率为93.33%，高于对照组的83.33%（P＜0.05）；两组HbA1c、FPG、2 hPG均低于治疗前，且观察组低于对照组（P＜0.05）；两组IL-6、TNF-α均小于治疗前，且观察组小于对照组（P＜0.05）；两组ET-1均低于治疗前，NO均高于治疗前，且观察组ET-1低于对照组，NO高于对照组（P＜0.05）；观察组不良反应发生率为6.67%，与对照组的10.00%比较，差异无统计学意义（P＞0.05）。结论 利拉鲁肽联合胰岛素强化治疗2型糖尿病临床疗效确切，可提高治疗总有效率，改善血糖和血管内皮功能指标，降低炎性因子水平，且不会增加临床不良反应，值得临床应用。
Abstract:
Objective To study the clinical efficacy of liraglutide combined with intensive insulin therapy in the treatment of type 2 diabetes mellitus, and its effect on inflammatory response and vascular endothelial function.Methods A total of 60 patients with type 2 diabetes mellitus who were diagnosed and treated in our hospital from June 2020 to June 2023 were selected as the research objects. They were divided into control group and observation group by random number table method, with 30 patients in each group. The control group was treated with intensive insulin therapy, and the observation group was treated with liraglutide on the basis of the control group. The clinical efficacy, blood glucose indexes [glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG), postprandial 2 h blood glucose (2 hPG)], inflammatory factors [interleukin 6 (IL-6), tumor necrosis factor α (TNF-α)] levels, vascular endothelial function indexes [endothelin 1 (ET-1), nitric oxide (NO)], and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.33%, which was higher than 83.33% in the control group (P<0.05). The levels of HbA1 c, FPG and 2 hPG in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05). The levels of IL-6 and TNF-α in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05) ,ET-1 in the two groups was lower than that before treatment, NO was higher than that before treatment, and ET-1 in the observation group was lower than that in the control group, and NO was higher than that in the control group (P<0.05). The incidence of adverse reactions in the observation group was 6.67%, which was compared with 10.00% in the control group, the difference was not statistically significant (P>0.05).Conclusion Liraglutide combined with intensive insulin therapy is effective in the treatment of type 2 diabetes mellitus, which can improve the total effective rate of treatment, improve blood glucose and vascular endothelial function indicators, reduce the level of inflammatory factors, and will not increase clinical adverse reactions. It is worthy of clinical application.

参考文献/References:

[1]黄倩,张玲,李佳芮,等.利拉鲁肽联合胰岛素治疗难治性2型糖尿病效果观察[J].山东医药杂志,2018,58(10):86-88.[2]孙艳,代丹娇,陈智伟,等.利拉鲁肽和恩格列净联合胰岛素治疗2型糖尿病的效果研究[J].河北医药,2020,42(21):3318-3320.[3]刘晶,赵培,陈稳,等.实时胰岛素泵治疗对2型糖尿病患者氧化应激及血管内皮功能的影响[J].河北医科大学学报,2019,40(12):1380-1383.[4]张洁,董闪闪,陈志花.利拉鲁肽联合短期胰岛素强化治疗初诊肥胖2型糖尿病患者疗效及对炎性因子的影响[J].疑难病杂志,2020,19(8):769-773.[5]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.[6]高晓燕,刘东兴,李凤华.利拉鲁肽治疗老年2型糖尿病患者对血管内皮功能及胰岛β细胞功能的影响[J].海南医学院学报,2016,22(14):1524-1527,1531.[7]马艳庆.利拉鲁肽与胰岛素强化治疗新发肥胖2型糖尿病的疗效比较[J].临床医学,2020,40(6):90-92.[8]李颖,黄芳华,顾瑾,等.利拉鲁肽联合强化降糖序贯方案对初诊2型糖尿病患者血糖控制效果及胰岛素第一时相分泌的影响[J].临床和实验医学杂志,2020,19(9):951-955.[9]陈松锦,张秀薇,陈伟坤,等.利拉鲁肽联合甘精胰岛素治疗首诊2型糖尿病的临床疗效[J].医学临床研究,2019,36(3):534-536.[10]边德志,王春雷,胥柯,等.利拉鲁肽对2型糖尿病患者内皮功能、免疫功能及相关因子水平的影响[J].海南医学院学报,2019,25(3):186-189.[11]刘烨,朱亦堃,刘炯.基础-餐时胰岛素强化联合西格列汀治疗新诊断2型糖尿病伴非酒精性脂肪肝的疗效及其对血管内皮功能的影响[J].中西医结合心脑血管病杂志,2020,18(7):1137-1141.[12]牛颜丽,吴国富.利拉鲁肽联合赖脯胰岛素25强化治疗新诊断2型糖尿病的远期疗效观察[J].浙江医学,2019,41(6):563-567,590.[13]李小景,荣秀花,欧宇苹,等.利拉鲁肽与胰岛素泵治疗超重2型糖尿病的疗效与安全性[J].中国医学创新,2019,16(27):35-38.[14]李欣,邱伟,邹慧.利拉鲁肽联合门冬胰岛素30注射液治疗2型糖尿病的效果[J].临床医学,2019,39(8):104-106.[15]李超杰,陈慧敏,濮先明.利拉鲁肽联合胰岛素强化治疗难治性2型糖尿病的临床疗效观察[J].青岛医药卫生,2019,51(4):256-259.[16]周瑞君.利拉鲁肽联合胰岛素治疗2型糖尿病过程中血糖变化及安全性分析[J].基层医学论坛,2019,23(14):1944-1945.[17]王喜玲.利拉鲁肽和西格列汀治疗胰岛素控制欠佳肥胖伴2型糖尿病患者的疗效比较[J].现代诊断与治疗,2019,30(14):2395-2397.[18]庞伟.分析联用利格列汀、胰激肽酶原治疗2型糖尿病对动态血糖的影响情况[J].泰山医学院学报,2019,40(4):312-313.[19]陈频,黄勤,徐向进,等.利拉鲁肽联合人脐带间充质干细胞治疗对2型糖尿病患者糖代谢及胰岛β细胞功能的作用[J].中华内科杂志,2016,55(5):349-354.[20]余淑芳.利拉鲁肽治疗血糖控制不佳的２型糖尿病患者的临床疗效及安全性研究[J].湖南师范大学学报(医学版),2019,16(2):57-60.

相似文献/References:

[1]刘 静.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者 血糖控制及体质量指数的影响[J].医学信息,2018,31(13):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
　LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Journal of Medical Information,2018,31(21):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
[2]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(21):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[3]张熠霖,皇晓燕,赵滢滢,等.糖尿病胰岛病变及胰岛β细胞胰岛素分泌损伤检测的整合实验相关经验探讨[J].医学信息,2019,32(01):18.[doi:10.3969/j.issn.1006-1959.2019.01.006]
　ZHANG Yi-lin,HUANG Xiao-yan,ZHAO Ying-ying,et al.Experience in the Integration Experiment of Diabetic Islet Lesions and Islet β-cell Insulin Secretion Damage Detection[J].Journal of Medical Information,2019,32(21):18.[doi:10.3969/j.issn.1006-1959.2019.01.006]
[4]曾小兵,朱长东,谢宝强.利拉鲁肽对首诊2型糖尿病患者血糖、血脂及T细胞亚群的影响[J].医学信息,2019,32(22):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
　ZENG Xiao-bing,ZHU Chang-dong,XIE Bao-qiang.Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2019,32(21):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
[5]牟 婷,张朝阳.胰岛素联合唑来膦酸治疗糖尿病骨质疏松症对患者血清指标的影响[J].医学信息,2019,32(22):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
　MU Ting,ZHANG Chao-yang.Effect of Insulin Combined with Zoledronic Acid on Serum Markers in Patients with Diabetic Osteoporosis[J].Journal of Medical Information,2019,32(21):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
[6]蔡 玲.不同胰岛素给药模式对高龄妊娠期糖尿病患者血糖控制及母婴结局的影响[J].医学信息,2020,33(04):141.[doi:10.3969/j.issn.1006-1959.2020.04.045]
　CAI Ling.Effects of Different Insulin Administration Modes on Blood Glucose Control andMaternal and nfant Outcomes in Elderly Gestational Diabetes Mellitus Patients[J].Journal of Medical Information,2020,33(21):141.[doi:10.3969/j.issn.1006-1959.2020.04.045]
[7]王 伟,刘 英.促胰岛素分泌抗糖尿病药物及其作用机制[J].医学信息,2020,33(11):30.[doi:10.3969/j.issn.1006-1959.2020.11.011]
　WANG Wei,LIU Ying.Insulin-promoting Anti-diabetic Drugs and Its Mechanism of Action[J].Journal of Medical Information,2020,33(21):30.[doi:10.3969/j.issn.1006-1959.2020.11.011]
[8]高艳红,哈海枫,陈小军,等.甘精胰岛素联合瑞格列奈治疗老年2型糖尿病的临床效果[J].医学信息,2021,34(01):152.[doi:10.3969/j.issn.1006-1959.2021.01.041]
　GAO Yan-hong,HA Hai-feng,CHEN Xiao-jun,et al.Clinical Effect of Insulin Glargine Combined with Repaglinide in the Treatment of Elderly Type 2 Diabetes[J].Journal of Medical Information,2021,34(21):152.[doi:10.3969/j.issn.1006-1959.2021.01.041]
[9]李 亚,宋大庆,韩翔宇,等.胰岛素强化降糖治疗对AMI伴高血糖患者心室重构及血清炎性因子影响的Meta分析[J].医学信息,2021,34(07):110.[doi:10.3969/j.issn.1006-1959.2021.07.030]
　LI Ya,SONG Da-qing,HAN Xiang-yu,et al.Meta-analysis of the Effect of Insulin Intensive Hypoglycemic Therapy on Ventricular Remodeling and Serum Inflammatory Factors in Patients with AMI with Hyperglycemia[J].Journal of Medical Information,2021,34(21):110.[doi:10.3969/j.issn.1006-1959.2021.07.030]
[10]王晓洲,吴仰帆,栾晓军.利拉鲁肽对肥胖T2DM患者促炎-抗炎系统及左心舒张功能的影响[J].医学信息,2021,34(22):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
　WANG Xiao-zhou,WU Yang-fan,LUAN Xiao-jun.Effects of Liraglutide on Pro-inflammatory-anti-inflammatory System and Left Ventricular Diastolic Function in Obese T2DM Patients[J].Journal of Medical Information,2021,34(21):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
[11]陶 蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
　TAO Lei,ZHANG Hong-jiang,FAN Zhong-yang.Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus[J].Journal of Medical Information,2021,34(21):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
[12]张 彤.利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性[J].医学信息,2022,35(05):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
　ZHANG Tong.Clinical Efficacy and Safety of Liraglutide Combined with Insulin in the Treatment of Newly Diagnosed Obese Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(21):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]

更新日期/Last Update: 1900-01-01